RVMD Price Prediction Next Week
Analysis and Insights
Technical Analysis:
RVMD's stock is currently trading at $37.92, near the lower end of its Fibonacci support level of $37.89. The stock has recently crossed above its 200-day moving average, a bullish signal indicating potential upward momentum. However, the RSI of 42 suggests the stock is not yet in oversold territory, and the MACD is slightly bearish, indicating some downward pressure.
Fibonacci Levels:
- Resistance: $41.63
- Support: $37.89
The stock is currently testing the lower end of its Fibonacci support level, which could act as a floor for the price in the short term.
News Sentiment and Analyst Ratings:
Analysts from Leerink Partners have maintained a bullish stance on RVMD, with a price target of $62.00, indicating strong upside potential. The stock is also part of the upcoming earnings releases, which could impact its price movement.
Prediction and Recommendation:
Based on the technical indicators and analyst sentiment, RVMD is expected to trade at $41.63 by the end of the next trading week. The bullish 200-day moving average cross and Fibonacci resistance level suggest a potential rebound. However, the current RSI and MACD suggest caution, and the stock may face resistance at higher levels.
Recommendation: Buy RVMD with a target price of $41.63 and a stop-loss at $37.89.
RVMD Similar Chart Price Prediction
The price of RVMD is predicted to go up 3.91%, based on the high correlation periods with CASI. The similarity of these two price pattern on the periods is 92.68%.
RVMD
CASI
Up: 3.91%Similarity: 92.68%
RVMD Revenue Forecast
RVMD EPS Forecast
RVMD Analyst's Forecast
Eliana Merle
UBS
Strong Buy
2025-01-08
Price Target
$65 → $71
Upside
+59.84%
UBS analyst Eliana Merle raised the firm's price target on Revolution Medicines to $71 from $65 and keeps a Buy rating on the shares as part of a broader note on the U.S. Pharmaceuticals and Biotechnology industry. The firm believes BioPharma will find it difficult to outperform against a more uncertain macro backdrop in the short-term, and thinks President-elect Trump will be capable of enacting significant legislative change, and that unpredictability is expected to cast a shadow over the space, the analyst tells investors in a research note. There will be continued uncertainty in the space until there is more clarity on Trump's changes, UBS says.
Robert Driscoll
Wedbush
Buy
2024-12-06
Price Target
$70 → $67
Upside
+39.38%
Michael Schmidt
Guggenheim
Strong Buy
2024-12-03
Price Target
$82 → $87
Upside
+80.39%
